DRUG NEWS: FDA panel warns of cancer risks

April 2005 
Volume 35  Number 4
Pages 30 - 30
  PDF Version Available!

© 2005 Lippincott Williams & Wilkins, Inc. Volume 35(4)             April 2005             p 30 FDA panel warns of cancer risks [DRUG NEWS: TOPICAL ECZEMA THERAPY]

An FDA advisory panel has recommended aggressive steps to warn consumers about cancer risks associated with two topical prescription drugs, pimecrolimus (Elidel) and tacrolimus (Protopic), which are indicated to treat atopic dermatitis (eczema) in certain patients. Both drugs work by suppressing the immune system and are approved for use in patients age 2 and older.

Among its recommendations, the advisory panel urged adding a prominent “black box” to labels warning of an increased risk of certain cancers, especially among children. Although administered topically, the drugs can be absorbed through the skin; because children have a greater ratio of body surface area to body mass than adults, they're especially vulnerable ...

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events